|
Gene: MCM9 |
Gene summary for MCM9 |
Gene summary. |
Gene information | Species | Human | Gene symbol | MCM9 | Gene ID | 254394 |
Gene name | minichromosome maintenance 9 homologous recombination repair factor | |
Gene Alias | C6orf61 | |
Cytomap | 6q22.31 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9NXL9 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
254394 | MCM9 | CCI_1 | Human | Cervix | CC | 2.67e-04 | 5.28e-01 | 0.528 |
254394 | MCM9 | CCI_2 | Human | Cervix | CC | 2.95e-05 | 5.65e-01 | 0.5249 |
254394 | MCM9 | CCI_3 | Human | Cervix | CC | 9.75e-04 | 4.66e-01 | 0.516 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Cervix | CC: Cervix cancer | |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
N_HPV: HPV-infected normal cervix |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00062602 | Cervix | CC | DNA replication | 48/2311 | 260/18723 | 2.70e-03 | 1.85e-02 | 48 |
GO:00323923 | Cervix | CC | DNA geometric change | 21/2311 | 90/18723 | 2.71e-03 | 1.85e-02 | 21 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MCM9 | SNV | Missense_Mutation | c.100N>A | p.Glu34Lys | p.E34K | Q9NXL9 | protein_coding | tolerated(0.1) | possibly_damaging(0.85) | TCGA-AG-3885-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | |
MCM9 | SNV | Missense_Mutation | rs182397736 | c.572N>T | p.Ser191Leu | p.S191L | Q9NXL9 | protein_coding | deleterious(0) | possibly_damaging(0.719) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MCM9 | SNV | Missense_Mutation | c.1124C>G | p.Thr375Ser | p.T375S | Q9NXL9 | protein_coding | deleterious(0.01) | probably_damaging(0.993) | TCGA-AG-4021-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
MCM9 | SNV | Missense_Mutation | novel | c.629N>T | p.Arg210Met | p.R210M | Q9NXL9 | protein_coding | deleterious(0) | probably_damaging(0.938) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MCM9 | SNV | Missense_Mutation | novel | c.1636N>A | p.Leu546Ile | p.L546I | Q9NXL9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MCM9 | SNV | Missense_Mutation | novel | c.973N>A | p.Ala325Thr | p.A325T | Q9NXL9 | protein_coding | deleterious(0.03) | probably_damaging(0.956) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MCM9 | SNV | Missense_Mutation | rs754615634 | c.2321N>T | p.Ser774Leu | p.S774L | Q9NXL9 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MCM9 | SNV | Missense_Mutation | novel | c.808G>T | p.Val270Leu | p.V270L | Q9NXL9 | protein_coding | deleterious(0) | possibly_damaging(0.846) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MCM9 | SNV | Missense_Mutation | novel | c.1037N>A | p.Ser346Tyr | p.S346Y | Q9NXL9 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MCM9 | SNV | Missense_Mutation | c.233T>G | p.Leu78Trp | p.L78W | Q9NXL9 | protein_coding | deleterious(0.01) | benign(0.069) | TCGA-AP-A0LF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |